1 Emerging-Market Threat to Big Pharma

The biggest players in the pharmaceutical space, including stalwarts Pfizer, Merck, and Bristol-Myers Squibb, are facing headwinds from the patent cliff. Pfizer's blockbuster drug, Lipitor, lost patent protection last year, and year-over-year sales of the drug were more than halved last quarter by generic competition. Patents for Merck's asthma drug Singulair and Bristol-Myers Squibb's blood thinner Plavix also recently expired. These companies are searching for fresh revenue streams that can quickly boost sales.

In addition to the development of new drugs, many pharmaceutical companies are targeting revenue growth from patients in emerging markets. However, litigation between German drugmaker Bayer and the Indian government suggests that these markets may become increasingly difficult to enter.

Bayer isn't alone. Biotech company Gilead is also trying to protect its intellectual property for an HIV drug in India, and industry giant Novartis is spending time in Indian courts trying to uphold its patent for oncology therapeutic Glivec.

In the following video, analysts Brenton Flynn and Max Macaluso discuss the woes of the drug industry and the international patent issues that you need to think about before investing in this sector.

Profiting from our increasingly global economy can be as easy as investing in your own backyard. Our free report "3 American Companies Set to Dominate the World" shows you how. Click here to get your free copy before it's gone.

Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool owns shares of Apple and McDonald's. Motley Fool newsletter services recommend Apple, Gilead Sciences, McDonald's, and Novartis. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2010466, ~/Articles/ArticleHandler.aspx, 11/28/2014 4:52:21 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 17,828.24 0.49 0.00%
S&P 500 2,067.56 -5.27 -0.25%
NASD 4,791.63 4.31 0.09%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

11/28/2014 1:00 PM
BMY $59.05 Up +0.19 +0.32%
Bristol-Myers Squi… CAPS Rating: ****
GILD $100.32 Up +0.02 +0.02%
Gilead Sciences CAPS Rating: *****
MRK $60.40 Up +0.65 +1.09%
Merck & Co., Inc. CAPS Rating: ****
NVS $96.65 Up +1.09 +1.14%
Novartis CAPS Rating: *****
PFE $31.15 Up +0.05 +0.16%
Pfizer CAPS Rating: ****

Advertisement